Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Non-Current Liabilities (2023 - 2025)

Historic Total Non-Current Liabilities for Krystal Biotech (KRYS) over the last 3 years, with Q4 2025 value amounting to $110.5 million.

  • Krystal Biotech's Total Non-Current Liabilities rose 228.71% to $110.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $110.5 million, marking a year-over-year increase of 228.71%. This contributed to the annual value of $110.5 million for FY2025, which is 228.71% up from last year.
  • As of Q4 2025, Krystal Biotech's Total Non-Current Liabilities stood at $110.5 million, which was up 228.71% from $99.1 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Total Non-Current Liabilities ranged from a high of $110.5 million in Q4 2025 and a low of $39.7 million during Q4 2023
  • In the last 3 years, Krystal Biotech's Total Non-Current Liabilities had a median value of $95.3 million in 2024 and averaged $89.2 million.
  • In the last 5 years, Krystal Biotech's Total Non-Current Liabilities soared by 17204.26% in 2024 and then surged by 228.71% in 2025.
  • Krystal Biotech's Total Non-Current Liabilities (Quarter) stood at $39.7 million in 2023, then surged by 172.04% to $108.0 million in 2024, then grew by 2.29% to $110.5 million in 2025.
  • Its last three reported values are $110.5 million in Q4 2025, $99.1 million for Q3 2025, and $94.9 million during Q2 2025.